Neuromuscular Block
15
0
0
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
67%
10 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Evaluation of the New Acceleromyograph TOF 3D
Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery
Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy
Neuromuscular Blockade for Optimising Surgical Conditions During Spinal Surgery
D Vitamin Effects on Neuromuscular Blocker Reverse Time
Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery
Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty
Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy
Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block
Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy
Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair
Sugammadex and Neostigmine at Shallow Neuromuscular Blockade
Efficacy of Sugammadex in Magnesium Pretreated Patients
The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium